JPET Introducing ALZET?ew Model 2006 Pump

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Journal of Pharmacology And Experimental Therapeutics Fast Forward
First published on May 20, 2005; DOI: 10.1124/jpet.105.085332


This Article
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
jpet.105.085332v1
314/2/552    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Jurgens, C. W.D.
Right arrow Articles by Doze, V. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Jurgens, C. W.D.
Right arrow Articles by Doze, V. A.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH


Received for publication March 18, 2005.
Revised May 14, 2005.
Accepted for publication May 17, 2005.

{beta}1 Adrenergic Receptor-Mediated Enhancement of Hippocampal CA3 Network Activity

Chris W.D. Jurgens 1, Katie E. Rau 1, Chris A. Knudson 1, Jacob D. King 1, Patrick A. Carr 1, James E. Porter 1, Van A. Doze 1*

1 University of North Dakota

* Address correspondence to: E-mail: vdoze{at}medicine.nodak.edu

Abstract

Norepinephrine is an endogenous neurotransmitter distributed throughout the mammalian brain. In higher cortical structures such as the hippocampus, norepinephrine, via {beta} adrenergic receptor (AR) activation, has been shown to reinforce the cognitive processes of attention and memory. In this study, we investigated the effect of {beta}1AR activation on hippocampal CA3 network activity. AR expression was first determined using immunocytochemistry with antibodies against {beta}1ARs, which were found to be exceptionally dense in hippocampal CA3 pyramidal neurons. CA3 network activity was then examined in vitro using field potential recordings in rat brain slices. The selective {beta}AR agonist isoproterenol caused an enhancement of hippocampal CA3 network activity, as measured by an increase in frequency of spontaneous burst discharges recorded in the CA3 region. In the presence of {alpha}AR blockade, concentration-response curves for isoproterenol, norepinephrine and epinephrine suggested that a {beta}1AR was involved in this response, as the rank order of potency was isoproterenol > norepinephrine = epinephrine. Finally, equilibrium dissociation constants (pKb) of subtype-selective {beta}AR antagonists were functionally determined to characterize the AR subtype modulating hippocampal CA3 activity. The selective {beta}1AR antagonists, atenolol and metoprolol, blocked isoproterenol-induced enhancement with apparent Kb values of 85±36 and 3.9±1.7nM, respectively. In contrast, the selective {beta}2AR antagonists, ICI-118,551 and butoxamine, inhibited isoproterenol-mediated enhancement with apparent low affinities (Kb = 222±61 and 9,268±512nM, respectively). Together, this pharmacological profile of subtype-selective {beta}AR antagonists indicates that in this model, {beta}1AR activation is responsible for the enhanced hippocampal CA3 network activity initiated by isoproterenol.


Key words: adrenergic receptor, catecholamine, characterization, extracellular field recording, hippocampus, pyramidal neuron





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2005 by the American Society for Pharmacology and Experimental Therapeutics.